Trinity Biotech plc — Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. The filing is an annual report, not a standalone Q4 filing; quarterly Q4 results are not separately disclosed in the provided text. Financial statements are prepared under IFRS in U.S. dollars.
Business context
Trinity Biotech develops, manufactures and markets diagnostic products for clinical laboratories and point-of-care use, including tests for infectious diseases, HIV, diabetes, hemoglobin disorders and autoimmune diseases. It also operates a U.S. autoimmune reference laboratory and supplies raw materials to life-science and research customers. Products are sold in approximately 100 countries through direct sales, distributors and strategic partners.
Key financial metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $93.0 million | $102.0 million | Down 8.8% |
| Gross profit | $38.1 million | $48.6 million | Down $10.5 million |
| Gross margin | 41.0% | 47.6% | Down 660 basis points |
| Operating profit | $6.6 million | $0.1 million | Improved |
| Profit/(loss) from continuing operations | $0.9 million | $(6.0) million | Improved |
| Net profit/(loss) | $0.9 million | $(6.4) million | Improved |
| Net cash from operating activities | $13.2 million | $23.8 million | Down $10.5 million |
| Capitalized development expenditure | $6.8 million | $6.9 million | Broadly stable |
| Cash and cash equivalents | $25.9 million | $27.3 million | Down $1.4 million |
| Total borrowings carrying value | $99.2 million | $102.6 million | Down $3.5 million |
| Equity attributable to owners | $(0.3) million | $(2.2) million | Deficit reduced |
Product revenue was $74.7 million, clinical laboratory services revenue was $7.9 million and point-of-care revenue was $10.3 million. Revenue by customer location was $57.8 million in the Americas, $25.5 million in Asia/Africa and $9.7 million in Europe.
Operating cash flow declined primarily because of lower operating cash generation and higher working-capital outflows. Investing cash outflow was $8.7 million, principally comprising $6.9 million of capitalized intangible development costs and $1.8 million of property, plant and equipment expenditure. Financing cash outflow was $6.0 million.
Material changes versus the prior comparable period
- Revenue declined primarily because 2020 benefited from exceptional demand and pricing for PCR viral transport media, while capacity expansion globally reduced 2021 prices and demand.
- Clinical laboratory goods revenue fell 11.4%, while point-of-care revenue increased approximately 12% due mainly to higher HIV sales in Africa.
- Diabetes-related testing revenue increased approximately 20% as testing schedules normalized, partly offset by lower hemoglobinopathy revenue following the U.S. Ultra II instrument recall.
- Gross margin contracted materially because of lower viral transport media pricing, lower margins in the Fitzgerald life-science supply business and the absence of certain 2020 government payroll supports.
- Operating profit improved despite lower revenue, supported by lower selling, general and administrative expense, lower impairment charges and $4.7 million of other operating income, primarily forgiven U.S. Paycheck Protection Program loans and related COVID-19 support.
- Impairment charges fell to $6.9 million from $17.8 million. The 2021 charges included approximately $5.0 million for Immco Diagnostics, $1.0 million for Trinity Biotech Brazil and $0.9 million related to a development project.
- The workforce declined to 477 employees from 543, reflecting cost-reduction actions and facility changes.
Debt, liquidity and going concern
- At December 31, 2021, the balance sheet classified $83.3 million of exchangeable notes as current because holders could require repurchase at par beginning April 1, 2022. Total borrowings, including lease and other obligations, had a carrying value of approximately $99.2 million.
- In January 2022, the Company drew an $81.25 million senior secured Perceptive Advisors term loan, issued 5.3 million ADSs and paid approximately $86.7 million to retire approximately 99.7% of the exchangeable notes. The term loan matures in January 2026, bears interest at 11.25% plus the greater of one-month LIBOR or 1%, and is secured by substantially all company assets.
- The Perceptive facility requires at least $5.0 million of unrestricted cash and compliance with minimum-revenue covenants. A covenant breach could accelerate the debt and permit enforcement against pledged assets.
- Management concluded that the Group could continue as a going concern for at least 12 months from the report date, relying on cash generation, refinancing and external financing. The 2021 balance sheet nevertheless showed net current liabilities and a shareholders’ equity deficit.
- In April 2022, Trinity announced a proposed $45 million MiCo strategic investment, consisting of approximately $25.2 million of equity and a $20 million seven-year junior convertible note. The investment was subject to customary Korean approvals and was intended primarily to repay part of the Perceptive term loan.
Guidance, outlook and unusual items
- Management expected non-COVID product demand to increase in 2022 as vaccination programs enabled more patients to return to physicians. Demand for COVID-related products remained highly uncertain.
- The Company expected to launch a rapid COVID-19 antigen test and sought CE marking for professional use in the second quarter of 2022. It also planned to submit the Premier Resolution hemoglobin analyzer to the FDA in 2022.
- TrinScreen HIV received World Health Organization approval in February 2022, opening a potential HIV screening market that management estimated at approximately $150 million annually.
- The Company wrote off the COVID-19 rapid antibody test development asset because the FDA did not prioritize its EUA application and management concluded that demand would be limited. Resources were redirected toward a COVID-19 antigen test.
- Material uncertainties include COVID-19 demand volatility, supply-chain disruption, pricing pressure, product recalls, FDA and other regulatory requirements, foreign exchange movements, customer and distributor concentration, and the ability to satisfy debt covenants and raise additional capital.
- The filing reports no material pending legal proceedings known to the Company. Potential grant repayment obligations were approximately $3.1 million if specified conditions were not met.
Most important facts for investors to verify
- Whether the MiCo transaction closed, received required approvals and generated the expected $45 million of funding.
- Current compliance with the Perceptive term-loan cash and minimum-revenue covenants, including the remaining principal balance and effective interest cost.
- Post-2021 revenue trends, gross margin and demand for viral transport media and other COVID-related products.
- Regulatory status of the Premier Resolution, rapid COVID-19 antigen test and other products, including remediation related to the FDA warning letter and prior recalls.
- Whether inventory reserves, capitalized development costs, goodwill and other intangible assets require further impairment.
- Potential dilution from the ADSs issued in the note retirement, Perceptive warrants for 2.5 million ADSs and outstanding options and warrants.
- Liquidity after debt refinancing, expected operating cash flow and the Company’s ability to fund approximately $6.5 million to $7.5 million of planned 2022 development expenditure.